A guidance raise built on Vyepti and partner-market timing collides with the Bexicaserin DEE readout — and a new R&D chief's first full call.
HLUYY · Earnings Call · 2026-11-11
Lundbeck's Scale Phase Meets Its Binary Moment
The guidance upgrade is real — but not all of it is operational
Lundbeck used its Q3 call to declare the end of its three-year “focus phase” and the start of a “scale phase.” The headline was a raised full-year outlook: revenue growth of 11-12% and adjusted EBITDA growth of 15-19%, both at constant exchange rates. CEO Charl van Zyl framed it as proof that the strategy has worked: “we are therefore very confident in raising our guidance on revenue to 11-12% and adjusted EBITDA at 15-19%” — Charl van Zyl, Executive (likely CEO) · 2026-11-11. That is a genuine change from August, when CFO Joerg Hornstein was explicit that the company had not yet upgraded: “We haven't upgraded our guidance, but I also tried to state that we are trending towards the upper end of the guidance” — Joerg Hornstein, CFO · 2026-08-19. The total revenue guidance move is therefore the clearest signal in the report.
But the quality of the raise deserves a closer look. Revenue reached DKK 20.2 billion, up 13% at constant exchange rates, with underlying growth of 11%. Adjusted gross margin was 86.6%, pressured by partner-market commission costs and unfavorable product and geographic mix. More importantly, part of the EBITDA upgrade came from a lower R&D spending range — and Hornstein was quick to say that is not a saving.
This does not constitute a saving. This is purely a timing related effect. So when you ask whether you will see these expenses in next year, then I would confirm this.
Partner markets also helped: management said the first half benefited from inventory build and phasing, softened in Q3, and that sell-out trends are better than expected. That is a better outcome than the old assumption of a declining business, but it is still a timing-sensitive line. The upgrade is real; the mix is not all clean operating leverage.
Vyepti is the engine; the market is being asked to re-underwrite it
The commercial story is increasingly Vyepti-first. Global Vyepti revenue reached DKK 4.533 billion, growing 45% at constant exchange rates, with U.S. growth of 46%. Management said Vyepti demand grew 39.3% versus 15.6% for the anti-CGRP market, and Tom Gibbs called it the fastest-growing brand in the category: “Vyepti remains the fastest growing brand in the anti CGRP market, with Vyepti demand growing 39.3% versus 15.6% for the market” — Thomas E. Gibbs, Executive (likely Chief Commercial Officer or similar) · 2026-11-11. Europe and international grew 41%, with France and Spain leading, and Japan approval gives Lundbeck a new launch runway. The commercial strategy is also shifting Vyepti earlier in the treatment paradigm — from fourth or fifth line toward second and third line — where Gibbs said a share point is worth 4.2x the volume.
That is why the December 8 Capital Markets event matters. Management has promised more detail on Vyepti peak sales and on bocunebart, the anti-PACAP migraine asset that is expected to enter Phase III by year-end. The pitch is a migraine franchise, not a single brand: Vyepti on the CGRP side, bocunebart on the PACAP side, complementary rather than cannibalistic. Rexulti remains the second pillar — DKK 5.1 billion in the first nine months, up 13% at constant exchange rates, with AAD TRx demand up 29% and MDD up 13.7%. But Rexulti also carries the clearest medium-term overhang: the 65+ segment is now 37% of TRx, and management is waiting for IRA negotiated pricing to be announced at the end of the month, with impact framed around 2028. The resilience is credible; the policy risk is not going away.
The pipeline is now a binary event, not a slide deck
The real story is Bexicaserin. Lundbeck is weeks away from the DEEp OCEAN headline readout in developmental epileptic encephalopathies, with DEEp SEA following in Q1 2027. Tarek Samad, in his first full quarterly call as Head of R&D, was direct: “we are on track for Deep Ocean headline results, by the end of the quarter with Deep Sea results expected in Q1 27” — Tarek Samad, Head of R&D · 2026-11-11. The mechanism is a selective 5-HT2C agonist intended to reduce hyperexcitability across a heterogeneous patient population with more than a thousand possible genetic etiologies. The Phase 2 PACIFIC open-label extension showed up to 59.3% sustained seizure reduction at 12 months, and the FDA has granted Breakthrough Therapy designation. Management also aligned with the FDA on a twice-daily dosing label update post-approval, a convenience win for a pediatric population.
The bull case rests on a broad DEE label spanning Dravet, Lennox-Gastaut and other DEEs — a high unmet need area where single-mechanism drugs have historically struggled. The bear case is equally simple: this is a binary clinical readout, and placebo response in epilepsy trials is notoriously variable. Samad acknowledged the range but argued the drug effect should still separate. This is no longer a “pipeline story” told through slides; it is a near-term event that will reset the equity narrative. The same is true, with less urgency, for bocunebart in late stage development and amlinetug in multiple system atrophy, where pivotal results are guided to Q3 2027.
What management stopped emphasizing — and why it matters
The contrast with the prior call is revealing. In August, analysts pressed on orexin differentiation, psychedelics, and the timing of midterm targets. Management gave detailed answers on orexin chemistry and tolerability, and the R&D head at the time, Johan Luthman, was retiring. On this call, orexin got a single sentence — patient studies are underway — and psychedelics disappeared entirely. The new R&D leadership has re-centered the story on Bexicaserin, bocunebart, asedebart and the D1D2 Parkinson's asset. That is a purposeful rotation from exploratory optionality to nearer-term catalysts.
Midterm targets were also deferred again. In August, Hornstein said the company would update the market on midterm guidance around Q4/Q1: “we'll provide an update on how we think about midterm guidance around Q4 and Q1” — Joerg Hornstein, CFO · 2026-08-19. On this call, the same Q1 timing was repeated. That is not a broken promise, but it does mean investors are still waiting for the framework that would make the “scale phase” concrete. In the meantime, the balance sheet is stronger, leverage has come down, and management reiterated €2-3 billion of M&A firepower. The strategic logic is coherent: use Vyepti cash and partner-market savings to fund pipeline catalysts and bolt-on innovation.
The tension is that Lundbeck is asking the market to underwrite two things at once — a durable Vyepti migraine franchise and a binary DEE asset — while the guidance raise leans partly on partner-market timing and a lower R&D phasing. The stock story from here is less about the Q3 beat than about the next two prints: the Bexicaserin headline and the December 8 migraine deep dive. If those deliver, the “scale phase” language will look prescient. If they do not, the guidance upgrade will look like a well-timed bridge to a riskier conversation.